S. Rosenberg

Immunology · Journal of Clinical Oncology · 2001–2018

A researcher in the Science corpus: 52 papers; trusts 22 researchers and is trusted by 57 researchers here, as inferred from the citation graph.

Subfields

• Immunology — 281 citations into it; #45 of 2,160 by trust here, #27 by citations
• Oncology — 233 citations into it; #16 of 1,698 by trust here, #10 by citations
• Molecular Biology — 74 citations into it; #8,028 of 17,773 by trust here, #1,089 by citations
• Genetics — 60 citations into it; #2,222 of 6,854 by trust here, #254 by citations

Whom S. Rosenberg trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. M. Dudley
2. Jie Yang
3. R. Morgan
4. N. Restifo
5. P. Robbins
6. L. Gattinoni
7. J. Wunderlich
8. R. Sherry
9. C. Klebanoff
10. M. Hughes

Who trusts S. Rosenberg overall

1. L. Gattinoni
2. Jie Yang
3. L. Zitvogel
4. N. Restifo
5. T. Gajewski
6. S. Spranger
7. Lisette G. de Pillis
8. Padmanee Sharma
9. P. Robbins
10. M. Dudley

Papers from S. Rosenberg's perspective

Ordered by how strongly the researchers S. Rosenberg trusts endorse each paper. Same corpus, a different order for every researcher.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
3. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
4. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (Journal of immunotherapy)
5. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma (Nature Medicine)
6. Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (Science Translational Medicine)
7. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma (New England Journal of Medicine)
8. IL-2: The First Effective Immunotherapy for Human Cancer (Journal of Immunology)
9. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (Blood)
10. Cancer immunotherapy: moving beyond current vaccines (Nature Medicine)

Their papers

• Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells (2013) — 1,116 citations
• Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer (2010) — 628 citations
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. (2003) — 2,835 citations
• Cancer immunotherapy: moving beyond current vaccines (2004) — 3,071 citations
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. (2005) — 987 citations
• Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (2013) — 1,094 citations
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) — 1,605 citations
• Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells (2003) — 1,015 citations
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. (2010) — 1,314 citations
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade (2007) — 631 citations
• gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma (2011) — 808 citations
• Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer (2018) — 708 citations
• T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer (2016) — 1,181 citations
• Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients (2016) — 809 citations
• Immunogenicity of somatic mutations in human gastrointestinal cancers (2015) — 702 citations
• Adoptive cell transfer as personalized immunotherapy for human cancer (2015) — 2,295 citations
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. (2015) — 1,473 citations
• Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. (2015) — 649 citations
• IL-2: The First Effective Immunotherapy for Human Cancer (2014) — 1,162 citations
• PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. (2014) — 994 citations